CMN Weekly (12 January 2024) - Your Weekly CRISPR Medicine News

Some of the best links we picked up around the internet

By: Gorm Palmgren - Jan. 12, 2024
News

#CRISPRMED24

Top picks

Research

Industry

CRISPR screens

Detection

Reviews

Perspectives

  • An editorial in ACS Synthetic Biology discusses how CRISPR systems have revolutionised point-of-care diagnostics. CRISPR-based diagnostics, mainly using Cas12 and Cas13, are advancing point-of-care (POC) molecular diagnostics, especially for infectious diseases like COVID-19. These technologies enable sensitive, specific detection of pathogens and genetic markers. Despite their potential, challenges in affordability, sensitivity, and ease of use still need to be addressed for global application.

Conferences and webinars

  • Early bird discounted fees for the CRISPR Medicine Conference in Copenhagen on 23-25 April 2024 will soon expire, so hurry up to secure your ticket for the first European CRISPR conference ever. The event will bring European CRISPR research to the forefront, with six main tracks that cover the most important topics in the therapeutic gene-editing field: Tools, Delivery, Safety, Functional Genomics, Standards and Regulations, Pre-clinical Research and Clinical Trials.

News from CRISPR Medicine News

To get more of the CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagMissing linksHashtagNewsHashtagCMN Weekly

News: CMN Weekly (12 January 2024) - Your Weekly CRISPR Medicine News
News: CMN Weekly (12 January 2024) - Your Weekly CRISPR Medicine News
CLINICAL TRIALS
Renal Cell Carcinoma, RCC, (NCT06245915)
Sponsors:
Arsenal Biosciences, Inc.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Solid Tumors, (NCT06237881)
Sponsors:
M.D. Anderson Cancer Center
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Breast Cancer, BC, (NCT05812326)
Sponsors:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine